Michael Makris/LinkedIn
Nov 12, 2025, 04:42
Michael Makris on FDA Approval of GEVV-HEM Gene Therapy for Hemophilia
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”A biotechnology company (GeneVentiv Therapeutics) has received positive FDA feedback to develop their GEVV-HEM gene therapy for hemophilia.
This is AAV based gene therapy with human factor Va as the insert.
I will want a lot of animal data showing lack of thrombogenicity before human trials.”
Read the announcement here.
Stay updated with Hemostasis Today.
-
Dec 14, 2025, 16:06Dr Abdul Mannan: What’s Your Approach to Diagnosing Iron Deficiency in Tricky Cases?
-
Dec 14, 2025, 16:05Mark Young – 46 Shadow Gates: How Your Chromosomes Archive Ancestral Memory
-
Dec 14, 2025, 16:04NNHF Unveiled at ASH2025: a Bold New Chapter was Marked – Expanding Beyond Haemophilia Care to Include SCD and Thalassemia
-
Dec 14, 2025, 15:46Heghine Khachatryan about PVCS as Cause of Chronic Pelvic Pain and Lower-Extremity/Pelvic Varices in Women
-
Dec 14, 2025, 15:42Gianluca Franceschini – Prevention is the Future: Investing Today to Save Lives Tomorrow
-
Dec 14, 2025, 13:55Indunil Karunarathna: Anticoagulation Therapy in Atrial Fibrillation Risks and Benefits
-
Dec 14, 2025, 12:56Mentored by Riten Kumar, Sriveda Boyalakuntla Presents Key Research on Infection-Associated Thrombosis at ASH25
-
Dec 14, 2025, 12:54Paul Roscoe: Deeply Proud of the Mend Care Team in This Intervention
-
Dec 13, 2025, 20:23Wolfgang Miesbach: From Daily Pills to Remission after Short‑Course Therapy in ITP